Drug Information
Drug General Information | Top | |||
---|---|---|---|---|
Drug ID |
DM2Y8T
|
|||
Drug Name |
GSK2820151
|
|||
Drug Type |
Small molecular drug
|
|||
Indication | Solid tumour/cancer [ICD-11: 2A00-2F9Z; ICD-10: C00-D48; ICD-9: 140-199] | Phase 1 | [1] | |
Company |
GlaxoSmithKline
|
Target and Pathway | Top | |||
---|---|---|---|---|
Target(s) | Bromodomain and extraterminal domain protein (BET) | Target Info | Inhibitor | [1] |
KEGG Pathway | SNARE interactions in vesicular transport | |||
Reactome | COPII (Coat Protein 2) Mediated Vesicle Transport | |||
WikiPathways | miR-targeted genes in squamous cell - TarBase | |||
miR-targeted genes in muscle cell - TarBase | ||||
miR-targeted genes in lymphocytes - TarBase |
References | Top | |||
---|---|---|---|---|
REF 1 | ClinicalTrials.gov (NCT02630251) Dose Escalation Study of GSK2820151 in Subjects With Advanced or Recurrent Solid Tumors. U.S. National Institutes of Health. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.